Pharmaceuticals Industry Deals and Trends in January 2019 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

Pages: 99 Published: April 17, 2019 Report Code: GDHC0542MD

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for January 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2019 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2019 12

2.2.1 Bristol-Myers Squibb to Acquire Celgene 12

2.2.2 Eli Lilly Acquires Loxo Oncology for USD8 Billion 13

2.2.3 Genentech to Enter into Licensing Agreement with Adaptive Biotechnologies 14

2.2.4 Neurocrine Biosciences to Enter into Licensing Agreement with Voyager Therapeutics 15

2.2.5 Esperion Therapeutics Enters into Licensing Agreement with Daiichi Sankyo Europe 17

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2019 18

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2019 19

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20

3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2019 20

3.1.1 Top M&A Deals in January 2019 21

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2018 – January 2019 22

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2019 23

3.2.1 Top Equity Offering Deals in January 2019 24

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2018 – January 2019 25

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2019 27

3.3.1 Top PE/VC Deals in January 2019 28

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2019 29

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2019 30

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016–January 2019 32

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016–January 2019 33

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2019 34

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2018 – January 2019 35

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2019 36

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2019 37

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 38

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2018 – January 2019 40

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2018 – January 2019 41

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 42

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2019 44

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2019 44

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2019 45

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2018 – January 2019 46

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2018 – January 2019 47

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2018 – January 2019 48

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2018 – January 2019 50

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2019 51

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2019 52

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2019 52

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 54

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2019 54

5.1.1 Oncology – Deals of the Month 55

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2019 57

5.2.1 Central Nervous System – Deals of the Month 58

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2019 60

5.3.1 Infectious Diseases – Deals of the Month 62

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2019 64

5.4.1 Cardiovascular – Deals of the Month 65

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2019 67

5.5.1 Immunology – Deal of the Month 68

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, January 2019 70

5.6.1 Gastrointestinal – Deals of the Month 71

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, January 2019 73

5.7.1 Metabolic Disorders – Deals of the Month 74

6 Deal Summary by Geography 76

6.1 Pharmaceuticals & Healthcare, North America Deals, January 2019 76

6.1.1 North America – Deals of the Month 77

6.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2019 79

6.2.1 Europe – Deals of the Month 81

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2019 82

6.3.1 Asia-Pacific – Deals of the Month 83

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2019 85

6.4.1 Rest of the World – Deals of the Month 87

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 89

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2018 – January 2019 89

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2018 – January 2019 90

8 Further Information 91

8.1 Methodology 91

8.2 About GlobalData 92

8.3 Contact Us 92

8.4 Disclosure information 92

8.5 Disclaimer 93

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, January 2019 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2019 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2019 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2018 – January 2019 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2019 24

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 26

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 28

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2019 28

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2018 – January 2019 29

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2019 31

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 32

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2018 – January 2019 33

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 34

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 35

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 36

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2019 37

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 39

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2018 – January 2019 41

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2018 – January 2019 43

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 44

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 45

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 46

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2019 47

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2018 – January 2019 49

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2019 51

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2019 51

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2019 52

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2019 52

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 55

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 58

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 61

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 65

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 68

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 71

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 73

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 77

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 80

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 83

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 86

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 89

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 90

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), January 2019 18

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2019 19

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 20

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2018 – January 2019 22

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 23

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 25

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 27

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2018 – January 2019 29

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2019 30

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2019 31

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 32

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 34

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 35

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 36

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 38

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2018 – January 2019 40

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2018 – January 2019 41

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 42

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 44

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 45

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 46

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2018 – January 2019 47

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2018 – January 2019 48

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2018 – January 2019 49

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2019 50

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 54

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 57

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 60

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 64

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 67

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 70

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 73

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 76

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 79

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 82

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 85

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 89

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2018 – January 2019 90

$1,000

Can be used by individual purchaser only

$3,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.